Oncoloxía Traslacional
![Foto de Oncoloxía Traslacional](/img/grupo.png)
![Foto de Universidad de Navarra](/img/noimage_org.png)
Universidad de Navarra
Pamplona, EspañaPublicacións en colaboración con investigadores/as de Universidad de Navarra (9)
2024
-
Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study
Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 732-738
2023
-
Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer
Thrombosis Research, Vol. 232, pp. 133-137
-
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme
European Journal of Cancer, Vol. 182, pp. 3-14
-
SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)
Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2732-2748
2022
2019
-
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study
Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132
-
CDK4/6 inhibitor as a novel therapeutic approach for advanced bladder cancer independently of RB1 status
Clinical Cancer Research, Vol. 25, Núm. 1, pp. 390-402
-
Gene Expression Analyses in Non Muscle Invasive Bladder Cancer Reveals a Role for Alternative Splicing and Tp53 Status
Scientific Reports, Vol. 9, Núm. 1
-
Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression
Nature Medicine